P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
Yaxiong Lin(Mayo Clinic in Arizona), Sundar Jagannath(Mount Sinai Hospital), Mounzer Agha(Dana-Farber Cancer Institute), Adam D. Cohen(Penn Center for AIDS Research), Elisabeth K. O’Donnell(Harvard University), Can Zhou, Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Nikhil C. Munshi(Dana-Farber Cancer Institute), Lida Pacaud(Centro de Investigación del Cáncer), Abhinav Deol(Wayne State University), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), S. Z. Usmani(Memorial Sloan Kettering Cancer Center), C. C. Jackson(Janssen (United States)), Myo Htut(City of Hope), Thomas Martin(University of California, San Francisco), J. G. Berdeja(Sarah Cannon), Deepu Madduri(Johnson & Johnson (United States)), Tzu‐Min Yeh(Centro de Investigación del Cáncer), Enrique Zudaire(Centro de Investigación del Cáncer)
Cited by 3
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k